Helping our clients move healthcare forward
Deal Announcement
Leerink Partners Deal Announcement: Abivax
Leerink Partners Serves as Joint Global Coordinator and Bookrunner for Abivax’s (Nasdaq: ABVX) $236 Million U.S. Initial Public Offering
Published October 20, 2023More Deal Announcements
View all Deal Announcements
Deal Announcement
Leerink Partners Serves as Exclusive Financial Advisor to Freeline Therapeutics (Nasdaq: FRLN) on its Going-Private Transaction with Syncona (LON: SYNC)
November 2023
Deal Announcement
Leerink Partners Serves as Exclusive Financial Advisor and Placement Agent for Q32 Bio’s Proposed Merger with Homology Medicines (Nasdaq: FIXX) and Concurrent $42 Million Private Placement
November 2023
Deal Announcement
Leerink Partners Serves as Exclusive Financial Advisor for Graphite Bio’s (Nasdaq: GRPH) Proposed Merger with LENZ Therapeutics
November 2023
Featured Intelligence
View additional intelligenceSee also:
Capital Markets
Growth-oriented companies need an experienced partner with demonstrated capital-raising power
Learn More